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Summary: 
Cholangiocytes play a crucial role in the pathophysiology of cholestasis. However, research 
on human cholangiocytes has been restricted by challenges in long-term propagation and 
large-scale expansion of primary biliary epithelium. The advent of organoid technology has 
overcome this limitation allowing long-term culture of a variety of epithelia from multiple 
organs. Here, we describe 2 methods for growing human cholangiocytes in organoid format. 
The first applies to the generation of intrahepatic bile ducts using human induced pluripotent 
stem cells using a protocol of differentiation that recapitulates physiological bile duct 
development. The second method allows the propagation of primary biliary epithelium from 
the extrahepatic ducts or gallbladder. Both protocols result in large numbers of cholangiocyte 
organoids expressing biliary markers and maintaining key cholangiocyte functions. 
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1. Introduction 
The biliary epithelium plays a crucial role in the pathogenesis of cholestatic disorders. 
Cholangiocyte proliferation and death, their interaction with bile and their cross-talk with the 
inflammatory milieu of disease play a key role in the evolution of cholangiopathies (1–3). 
However, studies on primary biliary epithelium have been limited by poor access to tissue 
precluding large scale analyses and functional studies especially in human (3, 4). Isolation and 
culture of human biliary epithelial cells can provide unique insights in the pathophysiology and 
management of cholestatic diseases. It can enable the development of in vitro models of 
cholestasis based on human tissue and  advance therapeutics through the generation of high-
throughput drug screening platforms (4).  
Organoid technology enables growing primary epithelium in 3-dimensional culture conditions 
in the presence of growth factors or small molecules modulating Wnt signalling. Organoids 
were first generated from intestinal epithelium by Hans Clevers and colleagues (5) and this 
approach has since been applied to a diversity of organs including the biliary tree. The resulting 
biliary organoids have the potential to revolutionize the study of human cholangiocytes (4, 6–
10). Indeed, these 3-dimensional structure with an isolated central lumen is ideal for 
recapitulating key cholangiocyte functions, such as maintaining lumen homeostasis and 
transfer of water, electrolytes and bile acids (11–15). Furthermore, organoid culture is 
compatible with the propagation of both intrahepatic and extrahepatic cholangiocytes from 
primary tissue or induced pluripotent stem cells (iPSCs) (4, 7).  
Here, we describe 2 methods for generating cholangiocyte organoids (COs) from adult primary 
extrahepatic biliary epithelium (i.e. extrahepatic cholangiocyte organoids (ECOs)) (7) or iPSC-
derived cholangiocyte-like-cells (CLCs) (4). These 2 systems are complementary, thus ECOs 
represent mature extrahepatic cholangiocytes but their derivation requires access to primary 
tissue, while CLCs maintain characteristics of foetal intrahepatic cholangiocytes and can be 
easily generated through a skin biopsy, even in cases where access to primary biliary tissue is 
not possible (4, 6, 7).  
CLCs are generated from iPSCs following a protocol that recapitulates human bile duct 
development (Fig. 1). Intrahepatic bile ducts develop from bipotent hepatoblasts in the foetal 
liver, which can give rise to both hepatocytes and cholangiocytes (16). Periportal hepatoblasts, 
under the effect of TGF-β start expressing biliary markers, such as SOX9 and form a monolayer 
of early cholangiocytes surrounding the portal vein, known as ductal plate (16, 17). The ductal 
plate subsequently remodels under the effect of Notch signalling (16, 18) to form tubular 
structures, which elongate under the effect of non-canonical Wnt signalling and the planar cell 
polarity pathway (19). To reproduce this process in vitro, iPSCs are plated as a monolayer and 
differentiated into definitive endoderm (DE), anterior foregut progenitors (FP), bipotent 
hepatoblasts (HB) and cholangiocyte progenitors (CP) corresponding to the early monolayer 
of cholangiocytes comprising the ductal plate (4, 6). Cholangiocyte progenitors are 
subsequently passaged and re-suspended in Matrigel in 3-dimensional culture. Under these 
conditions, CPs remodel into organoids, develop a central lumen and exhibit key biliary 
markers and functions, such as γ-glutamyl transferase (GGT) and alkaline phosphatase (ALP) 
activity. 
The generation of ECOs requires access to primary biliary epithelium in the form of endoscopic 
retrograde cholangiopancreatography brushings, cholangioscopy biopsies or excised tissue 
(common bile duct or gallbladder). The biliary epithelium is mechanically dissociated from the 
rest of the tissue and resuspended in Matrigel in 3-dimensional culture conditions, giving rise 
to cholangiocyte organoids (ECOs) in 5-14 days. ECOs can subsequently be propagated for 
multiple passages maintaining their functional properties and expression of key biliary markers 
(7). For each passage, the Matrigel needs to be enzymatically digested, the cells are harvested, 
split typically in a 1:4-1:6 ratio and re-embedded in Matrigel or cryopreserved. 
2. Materials 
1. Chemically defined medium-PVA (CDM-PVA) for maintenance of iPSCs: mix 250 mL of 
F12 with GlutaMAX with 250 mL of Iscove's Modified Dulbecco's Medium (IMDM) 
containing 0.5 g of 87-90% hydrolyzed Poly(vinyl alcohol) (PVA). Add 5 mL of concentrated 
lipids, 20 μL of 1.25 g/mL thioglycerol, 350 μL of 10 mg/mL insulin, 250 μL of 30 mg/mL 
transferrin and 5 mL of 10,000 U/mL penicillin/streptomycin. Store at 4°C for up to 1 month. 
2. Medium for plating iPSCs: use CDM-PVA complemented with 10 ng/mL Activin and 12 
ng/mL bFGF as plating medium. 
3. RPMI/B-27 differentiation medium for FPs, HBs and CPs (500 mL): supplement 500 mL of 
RPMI-1640 with 10 mL of B-27 supplement containing insulin, 5 mL of Eagle s minimum 
essential medium (MEM) non-essential amino acids (MEM-NEAA) and 5 mL of 10,000 U/mL 
pen/strep. Store at 4°C for up to 1 month. 
4. Supplemented William’s E medium for 3-dimensional culture of CLCs and ECOs (WE+): 
Prepare 500 mL of William’s E (WE) medium containing 10mM nicotinamide, 17 mM sodium 
bicarbonate, 0.2 mM ascorbic acid trisodium salt, 14 mM glucose, 6.3 mM sodium pyruvate, 
20 mM HEPES solution, 5 mL ITS+ premix, 0.1 μM dexamethasone, 2 mM Glutamine and 
50,000U pen/strep. Store at 4°C for up to 1 month. 
5. 66% (vol/vol) Matrigel solution for 3-dimensional organoid culture: mix thoroughly 1 
volume of supplemented WE medium and 2 volumes of Matrigel. Keep at 4°C to avoid 
Matrigel solidification. 
6. Required cytokines for differentiation of iPSCs into CLCs and maintenance of ECOs: the 
cytokines required are listed below. Reconstitute and store according to the manufacturer’s 
instructions. Prepare appropriate volume aliquots following reconstitution to avoid repeated 
freeze-thaw cycles. 
a. Recombinant human Activin A. 
b. Recombinant human bone morphogenetic protein 4 (BMP4). 
c. Recombinant human fibroblast growth factor (FGF) basic (bFGF), 146 aa. 
d. LY294002. 
e. CHIR99021. 
f. SB431542. 
g. Recombinant human keratinocyte growth factor-2 (also known as fibroblast growth factor 
10 or FGF10). 
h.  Retinoic acid. 
i. Rho-associated, coiled-coil containing protein kinase inhibitor Y27632 (ROCK inhibitor). 
j. Recombinant human epidermal growth factor (EGF). 
k. Recombinant human Dickkopf-related protein 1 (DKK-1). 
l. Recombinant human R-pondin-1. 
7. Cell dissociation buffer, enzyme-free, for passaging of CPs prior to embedding in Matrigel. 
Store at 4°C according to the manufacturer’s instructions. 
8. Cell recovery solution for passaging of ECOs and digestion of Matrigel. Store at 4°C 
according to the manufacturer’s instructions. 
9. Phosphate-buffered saline (PBS), pH 7.4 
10. Centrifuge. 
11. Plate heater. 
12. Incubator (37°C ± 1ºC, 90% ± 5% humidity, 5% ± 1% CO2). 
13. Laminar air flow cabinet. 
14. Thermostated water bath.  
3. Methods 
3.1. Differentiation of iPSCs to CLCs 
3.1.1 Plating of iPSCs for differentiation  
1. Plate iPSCs on vitronectin or gelatin-coated plastic tissue culture plates (see Notes 1-4).  
2. Incubate at 37°C overnight.  
 
3.1.2. Differentiation of iPSCs into DE (3 days) 
1. First day: replace the medium with CDM-PVA complemented with 100 ng/mL Activin A, 
80 ng/mL bFGF, 10 ng/mL BMP-4, 10 μM LY294002 and 3 μM CHIR99021. Incubate the 
cells at 37°C overnight. 
2. Second day: change the medium with CDM-PVA complemented with 100 ng/mL Activin 
A, 80 ng/mL bFGF, 10 ng/mL BMP-4, 10 μM LY294002. Incubate the cells at 37°C 
overnight. 
3. Third day: change the medium with RPMI/B27 medium complemented with 100 ng/mL 
Activin A and 80 ng/mL bFGF (see Notes 5-6). Incubate the cells at 37°C overnight. 
 
3.1.3. Differentiation of DE to FPs (5 days) 
Change the medium daily with RPMI/B27 medium complemented with 50 ng/mL Activin A 
(see Notes 5-6). 
 
3.1.4. Differentiation of FPs to HBs (4 days) 
Change the medium daily with RPMI/B27 medium complemented with 10 μM SB-431542 
and 50 ng/mL BMP-4 (see Notes 5-7). 
 
3.1.5. Differentiation of HBs to CPs (4 days) 
Change the medium daily with RPMI/B27 medium complemented with 50 ng/mL FGF10, 50 
ng/mL Activin-A and 3 μM Retinoic acid (see Notes 5-7). 
 
3.1.6 Passaging of CPs and embedding in Matrigel 
1. Before starting this step pre-warm a 24-well plate to 37°C on a plate heater placed in the 
tissue culture laminar air flow cabinet. 
2. Wash the cells with PBS once, add an adequate volume of cell recovery solution to cover 
the surface of the plate and incubate at 37°C for 15 minutes.  
3. Transfer the cells to a falcon tube, wash once with WE+ medium and centrifuge at 444xg 
for 3 minutes (see Note 8).  
4. Resuspend the pellet in 1 mL of WE+ medium. 
5. Gently dissociate the cell suspension into small 10-50 cells clumps through gentle pipetting 
with a p1000 pipette (see Notes 1 and 9). 
6. Centrifuge again at 444xg for 3 minutes.  
7. Resuspend the cell pellet in 66% (vol/vol) Matrigel supplemented with 20 ng/mL EGF and 
Rho kinase inhibitor 10 μΜ Y-27632 (see Notes 2, 5 and 9-14).  
8. Use a p1000 pipette to plate a 50 μL droplet of the cell suspension in each well of a pre-
warmed 24-well plate kept on the plate heater (see Note 15).  
9. Once the droplet starts solidifying (approximately 5 seconds) invert the plate and incubate 
at 37°C for 30 minutes (see Note 16).  
10. Following incubation, add an adequate volume of WE+ complemented with 20 ng/mL 
EGF and 10 μΜ Rho kinase inhibitor Y-27632 to cover the Matrigel domes(see Note 17).  
 
3.1.7 Differentiation of CPs to CLCs (10 days) 
Change the medium on alternate days with WE+ medium complemented with 20 ng/mL 
EGF. Organoids should emerge after 2-4 days. 
 
3.1.8 Characterization of the resulting CLCs 
The resulting CLC organoids can be characterized through quantative real-time PCR (QPCR) 
or immunofluorescence (IF) for the expression of biliary markers such as CK7, CK19, Sox9, 
GGT. Functional properties of CLC organoids such as GGT and ALP activity can be assessed 
at the end of this stage using commercially available kits (see Note 6). 
 
3.2. Isolation and propagation of ECOs 
3.2.1 Isolation of primary cholangiocytes 
1. For ERCP brushings wash the ERCP brush with the cells in a 15 mL falcon with WE+ 
medium and centrifuge the tube at 444xg (see Note 18). 
2. For surgically excised tissue, wash the tissue in a container with WE+ medium 3 times to 
remove bile and debris (see Notes 18-20). 
3. Transfer the tissue on an empty 10 cm plastic tissue culture plate. 
4. Dissect the tissue (bile duct or gallbladder) to expose the lumen. 
5. Add an adequate volume of WE+ medium to cover the tissue (see Note 20). 
6. Using a scalpel gently remove the biliary epithelium by scraping the lumen (see Note 21).  
7. Harvest the cell suspension in an appropriate volume falcon tube and collect the cells by 
centrifuging at 444xg for 3 minutes (see Note 20). 
8. Wash once by resuspending the cell pellet in 1 mL of WE+ media (see Note 20). 
9. Resuspend the cells in a 66% (vol/vol) Matrigel solution and plate them in 24-well plates 
as described in section 1.6 (see Note 22).  
10. Following incubation add 1 mL of WE+ media per well with 500 ng/mL R-spondin, 50 
ng/mL EGF, 100 ng/mL DKK-1 and 10 μΜ Rho kinase inhibitor Y-27632. 
11. Change media on alternate days, using WE+ media with 500 ng/mL R-spondin, 50 ng/mL 
EGF and 100 ng/mL DKK-1. 
12. Organoids should emerge within 2-5 days of culture 
 
3.2.2 Passaging of ECOs 
1. Aspirate the medium from the wells to expose the Matrigel domes (see Notes 1, 23-24). 
2. Add 500 μL of cell recovery solution directly on the Matrigel dome. 
3. Scrape the well with the tip of a p1000 pipette to disrupt the dome. 
4. Transfer the cell recovery solution containing the Matrigel dome fragments in a 15 mL 
tube using the p1000 pipette. 
5. Incubate at 4°C for 30 minutes. 
6. Centrifuge at 444xg for 3 minutes. 
7. Aspirate the supernatant (see Note 25). 
8. Wash the pellet with a minimum of 1ml of WE+ medium (see Notes 2, 26-27). 
9. Resuspend the cells in a 66% (vol/vol) Matrigel solution and plate them in 24-well plates 
as described in section 1.6.  
 
4. Notes 
1. Cell lines should be regularly karyotyped and tested for mycoplasma contamination. 
Karyotypic abnormalities or contamination can significantly affect the expression of biliary 
markers, function, and viability of the cells. 
2. Due to physiological variability in parameters such as proliferation capacity, some 
optimization of parameters such as seeding density and clump size may be required for 
working with different iPSC or ECO lines.  
3. A density of 1x106 cells per 10 cm plate is recommended. 
4. All media should be stored at 4°C for a maximum of 1 month. Cytokines should be stored 
at -20oC or -80oC according to the manufacturer’s instructions and aliquoted in appropriate 
volume aliquots to avoid repeat freeze-thaw cycles. 
5. Non-chemically defined components such as FBS, B-27 and Matrigel should be batch 
tested for their capacity to support proliferation, marker expression and function of the cells 
compared to primary controls. 
6. The efficiency of CLC differentiation depends on the differentiation efficiency of each 
step, which can be measured by flow cytometry analysis for key markers. The minimum 
requirements for each differentiation step are outlined below: 
DE: >90% SOX17 positive cells. 
FP: >95% GATA4 positive cells. 
HBs: >95% CK19 and AFP positive cells. 
CPs: >75% Sox9 positive cells. 
CLCs: > 75% CK7 and CK19 positive cells. 
7. The duration of the HB step is critical. The expression of hepatic markers (AFP) is driven 
by activin/TGF-β blockade (SB431542). Prolongation of this step will commit the cells to a 
hepatic fate, reducing their ability to reduce the expression of hepatocyte markers in the 
subsequent CP stage. Conversely, inadequate blockade with SB431542 will impact on the 
yield of this step for HBs. Therefore, the duration of the HB step can be modified accordingly 
for lines to fit lines with limited capacity for liver differentiation (prolonged SB431542 
treatment and/ or increased concentration) or reduced yield of CPs (reduction in the duration 
of the HB stage). 
8. If the cells have not detached spontaneously following incubation, mechanically dissociate 
them by scraping the plate with a p1000 pipette. 
9. Clump size is crucial for embedding the cells in Matrigel. Single cells and very small 
clumps demonstrate reduced viability and therefore fail to generate organoids, while very 
large clumps gravitate to the bottom of the plate and form a monolayer. Clump size should be 
optimized for each line and smaller sizes are recommended for very proliferative lines. 
10. Matrigel should be aliquoted in appropriate volume aliquots to avoid more than 1 freeze 
thaw cycle.  
11. Matrigel should always be kept on ice to avoid solidification. All equipment used with 
Matrigel such as pipette tips should be pre-cooled to 4°C. Work with Matrigel as quickly as 
possible, mix thoroughly and keep the suspension on ice to avoid Matrigel solidification.  
12. Take care to avoid the introduction of bubbles during the mixing stage which can prevent 
the optimal formation of Matrigel domes during plating. 
13. The total volume of the 66% (vol/vol) Matrigel solution used for resuspension can be 
calculated by multiplying the number of anticipated wells by 50 μL. 
14. We recommend a plating density of 1-2 x 105 cells/well. For this density, 1 well of 12 
well plate of CPs can yield 8-10 Matrigel domes. 
15. As the Matrigel-containing cell suspension droplet comes in contact with the warm 
surface of the plate, the droplet will start solidifying forming a hemispheric dome. 
16. Inverting the plate before the Matrigel solidifies fully is critical. This manoeuvre will 
prevent large clumps of cells from attaching to the bottom of the plate and expanding as a 
monolayer. 
17. For 1 well of a 24-well plate we recommend using 1 mL of medium. 
18. For the successful isolation of primary cholangiocytes it is crucial that the tissue is 
processed as soon as it is available to avoid reduction in cell viability. 
19. Bile is toxic for the cells, therefore adequate washes of the tissue are crucial for 
preserving cell viability. 
20. Wash the tissue during the isolation of primary cholangiocytes with PBS containing 1% 
(wt/vol) BSA or with WE+ media. Washes with low protein content such as PBS can result in 
loss of cells. 
21. This process will release small clumps of cholangiocytes in the medium. 
22. The same considerations as for CLCs apply when embedding primary cholangiocytes in 
Matrigel. However, primary cells are already broken into very small clumps by the 
mechanical dissociation and it is crucial that further dissociation of the cells after pelleting is 
avoided to preserve viability. 
23. ECO lines should be passaged promptly when the organoids are approximately 80% 
confluent. This period can vary between lines but is approximately 5 days. Delays in passaging 
can affect the quality and proliferation capacity of the organoid culture. 
24. Place the aspirator against the wall of the well and aspirate the medium by tilting the plate 
to avoid disrupting the Matrigel dome. 
25. At this stage undigested Matrigel remnants may form a layer above the cells. Even if this 
layer is not aspirated to avoid loss of cells, it will be cleared in the next wash. 
26. Washing with WE+ is crucial. Washes with low protein content such as PBS can result in 
loss of cells. 
27. At this stage the pellet can be split in multiple aliquots, depending on the number of wells 
required. We recommend a 1:5 split ratio and a plating density of 1-2 x 105 cells/well. 
 
 
Acknowledgements 
This work was financially supported by grants by the Addenbrooke’s Charitable Trust (ACT) 
(FS), Academy of Medical Sciences (FS), NIHR (FS), the Rosetrees Trust Interdisciplinary 
project grant “Generation and transplantation of a bioengineered human bile duct” (FS and 
LV). LV lab is funded by the ERC proof of concept grant Relieve-Chol, by the ERC advanced 
grant New-Chol and the core support grant from the Wellcome Trust and Medical Research 
Council to the Wellcome-Medical Research Council Cambridge Stem Cell Institute. 
 
 
References 
1.  Glaser S, Francis H, DeMorrow S, et al (2006) Heterogeneity of the intrahepatic 
biliary epithelium. World J Gastroenterol 12:3523–3536. 
2.  Lazaridis KN, Strazzabosco M, and Larusso NF (2004) The Cholangiopathies: 
disorders of biliary epithelia. Gastroenterology 127:1565–1577. 
3.  Lazaridis KN and LaRusso NF (2015) The cholangiopathies. Mayo Clin Proc 90:791–
800. 
4.  Sampaziotis F, Brito MC De, Madrigal P, et al (2015) Cholangiocytes derived from 
human induced pluripotent stem cells for disease modeling and drug validation. Nat 
Biotechnol 33:845–852. 
5.  Sato T, Vries RG, Snippert HJ, et al (2009) Single Lgr5 stem cells build crypt–villus 
structures in vitro without a mesenchymal niche. Nature 459:262–265. 
6.  Sampaziotis F, Brito MC de, Geti I, et al (2017) Directed differentiation of human 
induced pluripotent stem cells into functional cholangiocyte-like cells. Nat Protoc 
12:814–827. 
7.  Sampaziotis F, Justin AWAW, Tysoe OCOC, et al (2017) Reconstruction of the mouse 
extrahepatic biliary tree using primary human extrahepatic cholangiocyte organoids. 
Nat Med 23:954–963. 
8.  Tanimizu N, Miyajima A, and Mostov KE (2007) Liver Progenitor Cells Develop 
Cholangiocyte-Type Epithelial Polarity in Three-dimensional Culture. Mol Biol Cell 
18:1472–1479. 
9.  Dianat N, Dubois-Pot-Schneider H, Steichen C, et al (2014) Generation of functional 
cholangiocyte-like cells from human pluripotent stem cells and HepaRG cells. 
Hepatology 60:700–714. 
10.  Ogawa M, Ogawa S, Bear CE, et al (2015) Directed differentiation of cholangiocytes 
from human pluripotent stem cells. Nat Biotechnol 33:853–861. 
11.  Esteller A (2008) Physiology of bile secretion. World J Gastroenterol 14:5641–5649. 
12.  Marinelli RA, Tietz PS, Pham LD, et al (1999) Secretin induces the apical insertion of 
aquaporin-1 water channels in rat cholangiocytes. Am J Physiol 276:G280-286. 
13.  Boyer JL (2013) Bile formation and secretion. Compr Physiol 3:1035–1078. 
14.  Xia X, Francis H, Glaser S, et al (2006) Bile acid interactions with cholangiocytes. 
World J Gastroenterol 12:3553–3563. 
15.  Strazzabosco M (1997) Transport systems in cholangiocytes: Their role in bile 
formation and cholestasis. Yale J Biol Med 70:427–434. 
16.  Si-Tayeb K, Lemaigre FPFPFP, Duncan SASA, et al (2010) Organogenesis and 
development of the liver. Dev Cell 18:175–189. 
17.  Antoniou A, Raynaud P, Cordi S, et al (2009) Intrahepatic Bile Ducts Develop 
According to a New Mode of Tubulogenesis Regulated by the Transcription Factor 
SOX9. Gastroenterology 136:2325–2333. 
18.  Zong Y, Panikkar A, Xu J, et al (2009) Notch signaling controls liver development by 
regulating biliary differentiation. Development 136:1727–1739. 
19.  Strazzabosco M and Fabris L (2012) Development of the bile ducts: essentials for the 
clinical hepatologist. J Hepatol 56:1159–1170. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
 
 
 
 
Schematic outline of illustrating the various differentiation stages from induced Pluripotent Stem 
Cells to Cholangiocyte-like Cells. The corresponding method steps for each stage are indicated 
(described in the Methods section 3.1) 
 
 
 
